Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03646188 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)
A Phase 1 study, sponsored by SkinJect.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT03646188 is a Phase 1 study that was terminated before completion, run by SkinJect. The registered enrollment target is 13 participants.
The verdict
NCT03646188, a Phase 1 study, was terminated before completion, sponsored by SkinJect.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a Phase I study in participants with superficial or nodular Basal Cell Carcinoma (BCC), designed to assess dose limiting toxicities and maximum tolerated dose, efficacy, safety, and tolerability of dissolvable, tip-loaded, microneedle arrays containing doxorubicin (D-MNA).
Interventions
- DRUG Placebo-containing MNA
- DRUG 25 µg doxorubicin-containing MNA
- DRUG 50 µg doxorubicin-containing MNA
- DRUG 100 µg doxorubicin-containing MNA
- DRUG 200 µg doxorubicin-containing MNA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2020-06-10 |
| Est. Completion | 2021-05-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03646188
The ClinicalTrials.gov registry entry for NCT03646188 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SkinJect, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo-containing MNA is the first listed.
NCT03646188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03646188 about?
NCT03646188 is a clinical study titled "Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)". This is a Phase I study in participants with superficial or nodular Basal Cell Carcinoma (BCC), designed to assess dose limiting toxicities and maximum tolerated dose, efficacy, safety, and tolerability of dissolvable, tip-loaded, microneedle arrays containing doxorubicin (D-MNA).
What is the current status of trial NCT03646188?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2020-06-10. Estimated completion is 2021-05-04.
What interventions are being tested in trial NCT03646188?
The interventions under investigation include: Placebo-containing MNA (DRUG), 25 µg doxorubicin-containing MNA (DRUG), 50 µg doxorubicin-containing MNA (DRUG), 100 µg doxorubicin-containing MNA (DRUG), 200 µg doxorubicin-containing MNA (DRUG).
Who is sponsoring clinical trial NCT03646188?
This trial is sponsored by SkinJect, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.